343 related articles for article (PubMed ID: 34876795)
1. Survival and outcomes for co-infection of chronic hepatitis C with and without cirrhosis and COVID-19: A multicenter retrospective study.
Afify S; Eysa B; Hamid FA; Abo-Elazm OM; Edris MA; Maher R; Abdelhalim A; Abdel Ghaffar MM; Omran DA; Shousha HI
World J Gastroenterol; 2021 Nov; 27(42):7362-7375. PubMed ID: 34876795
[TBL] [Abstract][Full Text] [Related]
2. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
[TBL] [Abstract][Full Text] [Related]
3. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
McDonald SA; Pollock KG; Barclay ST; Goldberg DJ; Bathgate A; Bramley P; Dillon JF; Fraser A; Innes HA; Kennedy N; Morris J; Went A; Hayes PC; Hutchinson SJ
J Viral Hepat; 2020 Mar; 27(3):270-280. PubMed ID: 31696575
[TBL] [Abstract][Full Text] [Related]
4. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
5. All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response.
Miotto N; Mendes LC; Zanaga LP; Lazarini MSK; Goncales ESL; Pedro MN; Goncales FL; Stucchi RSB; Vigani AG
PLoS One; 2018; 13(7):e0199941. PubMed ID: 29990371
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.
Mallet V; Beeker N; Bouam S; Sogni P; Pol S;
J Hepatol; 2021 Oct; 75(4):848-855. PubMed ID: 33992699
[TBL] [Abstract][Full Text] [Related]
7. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
8. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of acute hepatitis E super-infections on chronic hepatitis B.
Chen C; Zhang SY; Zhang DD; Li XY; Zhang YL; Li WX; Yan JJ; Wang M; Xun JN; Lu C; Ling Y; Huang YX; Chen L
World J Gastroenterol; 2016 Dec; 22(47):10388-10397. PubMed ID: 28058019
[TBL] [Abstract][Full Text] [Related]
10. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 Mid-term Impact on Hepatocellular Carcinoma in Patients With Hepatitis C Chronic Infection.
Guler-Margaritis S; Mercan-Stanciu A; Toma L; Rusie D; Isac T; Dodot M; Zgura A; Bacalbasa N; Haineala B; Badiu DC; Serban D; Iliescu EL
In Vivo; 2021; 35(6):3377-3383. PubMed ID: 34697172
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
Fernández Carrillo C; Lens S; Llop E; Pascasio JM; Crespo J; Arenas J; Fernández I; Baliellas C; Carrión JA; de la Mata M; Buti M; Castells L; Albillos A; Romero M; Turnes J; Pons C; Moreno-Planas JM; Moreno-Palomares JJ; Fernández-Rodriguez C; García-Samaniego J; Prieto M; Fernández Bermejo M; Salmerón J; Badia E; Salcedo M; Herrero JI; Granados R; Blé M; Mariño Z; Calleja JL
Hepatology; 2017 Jun; 65(6):1810-1822. PubMed ID: 28170112
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status.
Cao Z; Zhang C; Zhao S; Sheng Z; Xiang X; Li R; Qian Z; Wang Y; Chen B; Li Z; Liu Y; An B; Zhou H; Cai W; Wang H; Gui H; Xin H; Xie Q
Infect Dis Poverty; 2022 May; 11(1):56. PubMed ID: 35578350
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.
Janczewska E; Kołek MF; Lorenc B; Klapaczyński J; Tudrujek-Zdunek M; Sitko M; Mazur W; Zarębska-Michaluk D; Buczyńska I; Dybowska D; Czauż-Andrzejuk A; Berak H; Krygier R; Jaroszewicz J; Citko J; Piekarska A; Dobracka B; Socha Ł; Deroń Z; Laurans Ł; Białkowska-Warzecha J; Tronina O; Adamek B; Tomasiewicz K; Simon K; Pawłowska M; Halota W; Flisiak R
World J Gastroenterol; 2021 May; 27(18):2177-2192. PubMed ID: 34025072
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
17. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
Vezali E; Aghemo A; Colombo M
Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
[TBL] [Abstract][Full Text] [Related]
18. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
Marjot T; Moon AM; Cook JA; Abd-Elsalam S; Aloman C; Armstrong MJ; Pose E; Brenner EJ; Cargill T; Catana MA; Dhanasekaran R; Eshraghian A; García-Juárez I; Gill US; Jones PD; Kennedy J; Marshall A; Matthews C; Mells G; Mercer C; Perumalswami PV; Avitabile E; Qi X; Su F; Ufere NN; Wong YJ; Zheng MH; Barnes E; Barritt AS; Webb GJ
J Hepatol; 2021 Mar; 74(3):567-577. PubMed ID: 33035628
[TBL] [Abstract][Full Text] [Related]
19. Poor outcomes in patients with cirrhosis and Corona Virus Disease-19.
Shalimar ; Elhence A; Vaishnav M; Kumar R; Pathak P; Soni KD; Aggarwal R; Soneja M; Jorwal P; Kumar A; Khanna P; Singh AK; Biswas A; Nischal N; Dar L; Choudhary A; Rangarajan K; Mohan A; Acharya P; Nayak B; Gunjan D; Saraya A; Mahapatra S; Makharia G; Trikha A; Garg P
Indian J Gastroenterol; 2020 Jun; 39(3):285-291. PubMed ID: 32803716
[TBL] [Abstract][Full Text] [Related]
20. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
